FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245654989> ?p ?o ?g. }

• W4245654989 endingPage "478" @default.
• W4245654989 startingPage "477" @default.
• W4245654989 abstract "Back to table of contents Previous article Next article LETTERFull AccessPossible Neuroleptic Malignant Syndrome Associated With PaliperidoneHarpreet S. Duggal,Harpreet S. DuggalSearch for more papers by this author,Published Online:1 Oct 2007AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail SIR: Paliperidone, the major active metabolite of risperidone, is the newest of the second generation antipsychotics shown to be effective in treating schizophrenia. 1 A case of a patient developing a possible neuroleptic malignant syndrome (NMS) on adding paliperidone to tapering doses of quetiapine and trifluoperazine is described. Early diagnosis in this patient may have aborted a full-blown NMS in this patient. Case Report“Mrs. A,” a 63-year-old woman, was admitted to the psychiatric unit for exacerbation of chronic paranoid schizophrenia. Her current medications included quetiapine 1300 mg/day in divided doses, trifluoperazine 40 mg/day in divided doses, and clonazepam 1 mg at bed time. On admission, her urine toxicology screen, serum chemistries, and blood counts were within normal limits. She had a urinary tract infection, which was treated with nitrofurantoin and a repeat urine analysis after a week was unremarkable. In the past, Mrs. A had tried risperidone, aripiprazole, olanzapine, and clozapine, but there was insufficient information to ascertain the response to these medications. Mrs. A was initially continued on the same doses of quetiapine and trifluoperazine as her adherence with these medications had been questionable. However, with no improvement in the symptoms for 8 days after admission, paliperidone was started at 6 mg/day. At the same time quetiapine taper was begun and it was discontinued over the next 5 days, while paliperidone was increased to 9 mg/day. Two days after starting paliperidone, trifluoperazine was discontinued. Mrs. A’s delusions and hallucinations showed marginal improvement on paliperidone. However, 6 days after starting paliperidone, Mrs. A started complaining of increased stiffness. She had cogwheel rigidity and dysarthria on examination and was started on benztropine 1 mg po b.i.d. Her rigidity worsened over the next 2 days (eight days after paliperidone was started) despite being on benztropine. The patient was noticed to be more “confused” by the staff and also displayed diaphoresis. A repeat urine analysis, serum chemistries and blood counts were unremarkable. Her vitals suggested tachycardia (116 bpm), labile blood pressure (116/73–153/93 mmHg), and a mild increase in temperature (99.6°F). A preliminary diagnosis of NMS was entertained and a stat creatine phosphokinase (CPK) showed a modest elevation at 313 U/liter (normal 24–170 U/liter). Paliperidone was discontinued the same day and bromocriptine 25 mg po t.i.d and dantrolene 25 mg po daily were started. Her CPK level, however, continued to rise and peaked at 607 U/liter 3 days after paliperidone was discontinued. Over the 5 days following the discontinuation of paliperidone, the patient had complete resolution of rigidity, confusion and autonomic instability and her CPK level dropped to 268 U/liter and then to 74 U/liter over the next 2 days. The patient was not on any antipsychotics during this time and was only receiving clonazepam 1 mg at bed time and benztropine 1 mg b.i.d. The patient was seen by neurology who recommended discontinuation of bromocriptine and dantrolene at that time.Eight days after stopping paliperidone, Mrs. A was restarted on quetiapine (gradually increased to 1200 mg/day) and, subsequently, trifluoperazine was also restarted and increased to the previous dose of 40 mg/day without any recurrence of symptoms of NMS. Benztropine was decreased to 0.5 mg b.i.d and the patient was discharged on this combination when her psychotic symptoms reached baseline.Comment This patient met the DSM-IV-TR criteria for NMS although hyperthermia was absent in this patient and other symptoms were mild in nature. This may be either due to the atypical presentation of NMS described with atypical antipsychotics or due to early recognition of the condition. 2 Paliperidone was implicated in this adverse effect because of the temporal relation between appearance of NMS symptoms and initiation of paliperidone and the failure of reemergence of NMS with the reintroduction of quetiapine and trifluoperazine. However, NMS has been described with neuroleptic discontinuation and the contribution of quetiapine and trifluoperazine in this presentation cannot be entirely excluded and the index neurotoxic reaction may have been a cumulative dose-related effect of the all the antipsychotics. 3 Premarketing data as per the package insert for paliperidone have described the occurrence of NMS with this drug and one patient developed possible NMS with it in a pivotal study. 1 , 4 However, a PubMed search through June 2007 using the key words ‘neuroleptic malignant syndrome’ and ‘paliperidone’ in English language literature did not yield any reports of NMS with paliperidone. This case underscores the importance of early recognition of NMS and also alerts the clinicians to its association with paliperidone, which is expected as NMS has been reported with risperidone. 5 This case also highlights the shortcomings of the current diagnostic criteria for NMS, which are silent on the atypical presentation of this syndrome. This assumes significance as the cornerstones of diagnosing NMS such as extreme temperature elevation and muscle rigidity may be less frequent with the atypical antipsychotics. 3 , 5 Thus, with the widespread use of atypical antipsychotics, criteria geared more toward the early recognition of the atypical presentation of NMS are desirable. This is in line with the contention that a false positive diagnosis of NMS with unnecessary discontinuation of antipsychotics and exposure to antidote treatment may be less harmful than allowing for the progression of NMS, which may be fatal. 5Herrick Memorial Hospital, Tecumseh, Mich.References1 . Kramer M, Simpson G, Maciulis V, et al: Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007; 27:6–14Google Scholar2 . Duggal HS, Kithas J: Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine (letter). Am J Psychiatry 2005; 162:397–398Google Scholar3 . Caroff SN, Mann SC, Campbell EC: Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Annals 2000; 30:314–321Google Scholar4 . Janssen, L.P: Paliperidone drug information. Titusville NJ, Janssen, L.P., 2006Google Scholar5 . Seitz DP: Diagnostic uncertainty in a case of neuroleptic malignant syndrome. Can J Emerg Med 2005; 7:266–272Google Scholar FiguresReferencesCited byDetailsCited byExpert Opinion on Drug Safety, Vol. 16, No. 3Atypical Neuroleptic Malignant Syndrome Associated With Paliperidone Long-Acting InjectionJournal of Clinical Psychopharmacology, Vol. 36, No. 3A Case Report of Probable Paliperidone ER-Induced Serotonin Syndrome in a 17-Year-Old Taiwanese Female With New Onset PsychosisMedicine, Vol. 95, No. 9Drugs in R&D, Vol. 15, No. 1Possible Paliperidone-Induced Neuroleptic Malignant Syndrome: A Case ReportArmağan Özdemir, M.D., Cana Aksoy-Poyraz, M.D., and Esra Kılıç-Yener, M.D.1 July 2012 | The Journal of Neuropsychiatry and Clinical Neurosciences, Vol. 24, No. 3Catatonia and Encephalopathy Associated With Paliperidone PalmitateJournal of Clinical Psychopharmacology, Vol. 32, No. 2Emergence of Neuroleptic Malignant Syndrome While Switching Between Risperidone and PaliperidonePo-Ren Teng, M.D., M.S., and Hsien-Yuan Lane, M.D., Ph.D.1 October 2011 | The Journal of Neuropsychiatry and Clinical Neurosciences, Vol. 23, No. 4Paliperidone-Induced Neuroleptic Malignant SyndromeRaghavendra Bheemappa Nayak, M.D., Govind S. Bhogale, M.D., D.P.M., Nanasaheb M. Patil, M.D., Sameeran S. Chate, M.D., D.P.M., Aditya Anand Pandurangi, M.B.B.S., and Veda N. Shetageri, M.B.B.S.1 January 2011 | The Journal of Neuropsychiatry and Clinical Neurosciences, Vol. 23, No. 1Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 35, No. 2Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia14 February 2011 | Journal of Central Nervous System Disease, Vol. 3Possible Neuroleptic Malignant Syndrome During Paliperidone AdministrationJournal of Clinical Psychopharmacology, Vol. 30, No. 1American Journal of Health-System Pharmacy, Vol. 67, No. 6American Journal of Health-System Pharmacy, Vol. 67, No. 15Risk of Neuroleptic Malignant Syndrome in Patients with Bipolar Disorder: A Retrospective, Population-Based Case-Control Study5 February 2010 | The International Journal of Psychiatry in Medicine, Vol. 39, No. 4Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome29 July 2008 | Annals of Pharmacotherapy, Vol. 42, No. 9Cochrane Database of Systematic Reviews Volume 19Issue 4 Fall, 2007Pages 477-478 Metrics PDF download History Published online 1 October 2007 Published in print 1 October 2007" @default.
• W4245654989 created "2022-05-12" @default.
• W4245654989 creator A5028822489 @default.
• W4245654989 date "2007-11-01" @default.
• W4245654989 modified "2023-09-27" @default.
• W4245654989 title "Possible Neuroleptic Malignant Syndrome Associated With Paliperidone" @default.
• W4245654989 doi "https://doi.org/10.1176/appi.neuropsych.19.4.477" @default.
• W4245654989 hasPublicationYear "2007" @default.
• W4245654989 type Work @default.
• W4245654989 citedByCount "9" @default.
• W4245654989 countsByYear W42456549892021 @default.
• W4245654989 crossrefType "journal-article" @default.
• W4245654989 hasAuthorship W4245654989A5028822489 @default.
• W4245654989 hasConcept C118552586 @default.
• W4245654989 hasConcept C187212893 @default.
• W4245654989 hasConcept C2776412080 @default.
• W4245654989 hasConcept C2777126507 @default.
• W4245654989 hasConcept C2777964233 @default.
• W4245654989 hasConcept C2780494398 @default.
• W4245654989 hasConcept C2908997079 @default.
• W4245654989 hasConcept C71924100 @default.
• W4245654989 hasConceptScore W4245654989C118552586 @default.
• W4245654989 hasConceptScore W4245654989C187212893 @default.
• W4245654989 hasConceptScore W4245654989C2776412080 @default.
• W4245654989 hasConceptScore W4245654989C2777126507 @default.
• W4245654989 hasConceptScore W4245654989C2777964233 @default.
• W4245654989 hasConceptScore W4245654989C2780494398 @default.
• W4245654989 hasConceptScore W4245654989C2908997079 @default.
• W4245654989 hasConceptScore W4245654989C71924100 @default.
• W4245654989 hasIssue "4" @default.
• W4245654989 hasLocation W42456549891 @default.
• W4245654989 hasOpenAccess W4245654989 @default.
• W4245654989 hasPrimaryLocation W42456549891 @default.
• W4245654989 hasRelatedWork W2007896655 @default.
• W4245654989 hasRelatedWork W2324836599 @default.
• W4245654989 hasRelatedWork W2366013553 @default.
• W4245654989 hasRelatedWork W4230118572 @default.
• W4245654989 hasRelatedWork W4253058075 @default.
• W4245654989 hasRelatedWork W4255771179 @default.
• W4245654989 hasRelatedWork W4311337120 @default.
• W4245654989 hasRelatedWork W4313201498 @default.
• W4245654989 hasRelatedWork W4380149880 @default.
• W4245654989 hasRelatedWork W4380203449 @default.
• W4245654989 hasVolume "19" @default.
• W4245654989 isParatext "false" @default.
• W4245654989 isRetracted "false" @default.
• W4245654989 workType "article" @default.